Recursion has hit 4 milestones in its Sanofi partnership over the last 18 months, as well as 1 with Roche. Recursion's ATM facility is also likely to be used opportunistically to raise cash.

Recursion Pharmaceuticals (RXRX) stock gains as the company plans a 20% workforce reduction to streamline operations and extend cash runway to Q4 2027. Read more here.

MIT and Recursion partner for AI drug discovery tool Freely available Boltz-2 algorithm can predict small-molecule binding affinities by Laura Howes ...

In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals (RXRX 0.70%) is slimming down and streamlining. After the biotech updated its strategy to do so ...

Factorial Inc. (Factorial), a leader in solid-state battery technology, today announced the launch of Gammatron™, a proprietary AI-driven simulation platform designed to accelerate the ...

Recently, two leading and long-established firms in the expanding AI drug discovery sector revealed an unexpected merger. In an approximate 75-25 agreement, Recursion Bio and Exscientia are set to ...

Discover real-time Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead ...

Recursion Pharmaceuticals will lay off roughly 20% of its workforce, affecting some 160 employees, in a bid to extend its cash runway. In an SEC filing on Tuesday, the Utah-based biotech announced ...